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C-peptide,acleavageproductoftheproinsulinmolecule,haslongbeenregardedasbiologicallyinert,servingmerelyasasurrogate
marker for insulin release. Recent ﬁndings demonstrate both a physiological and protective role of C-peptide when administered
to individuals with type I diabetes. Data indicate that C-peptide appears to bind in nanomolar concentrations to a cell surface
receptor which is most likely to be G-protein coupled. Binding of C-peptide initiates multiple cellular eﬀects, evoking a rise in in-
tracellularcalcium,increasedPI-3-kinaseactivity,stimulationoftheNa+/K+ ATPase,increasedeNOStranscription,andactivation
of the MAPK signalling pathway. These cell signalling eﬀects have been studied in multiple cell types from multiple tissues. Overall
these observations raise the possibility that C-peptide may serve as a potential therapeutic agent for the treatment or prevention
of long-term complications associated with diabetes.
Copyright © 2008 C. E. Hills and N. J. Brunskill. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
HistoricallyproinsulinC-peptide hasbeenregardedasanin-
ert byproduct of insulin synthesis and processing. In the last
decade, however, an enlarging body of evidence has emerged
from several laboratories reporting both in vitro and in vivo
eﬀects of C-peptide of great potential relevance to the patho-
physiology and treatment of diabetes. Observations that C-
peptide may exhibit characteristics of a peptide hormone
beneﬁcially aﬀecting nerve, renal and microvascular func-
tions in diabetic animals and in patients with diabetes [1–
7], have stimulated interest in the molecular mechanisms by
which cell signals elicited by C-peptide are transduced into
altered cell and organ behaviour.
2. A C-PEPTIDE RECEPTOR
Clearly if C-peptide has peptide hormone-like actions, it is
necessary to postulate the existence of a receptor. Indeed,
speciﬁc and displaceable binding of 125I-labelled C-peptide
was ﬁrst demonstrated by Flatt et al. [8]wh od e ri v e dac u rvi -
linearScatchardplotofspeciﬁcC-peptidebindingtopancre-
atic islet B-cells.
Subsequently, using retro sequence and all-D-amino acid
C-peptide enantiomers, Ido et al. [9] suggested that C-
peptide-inducedimprovementsinnervefunctionandvascu-
lar permeability blood ﬂow in diabetes through increases in
Na+,K+-ATPase activity did not result from C-peptide bind-
ing in a stereospeciﬁc manner to a receptor. Instead it was
hypothesised that biological activity of C-peptide was de-
pendent on poorly deﬁned membrane interactions that took
place due to structural features related to the C-peptide se-
quence, but independent of its direction or chirality. A mid-
portion sequence of C-peptide, largely conserved, and com-
prising a high proportion of nonpolar amino acids ﬂanking
a C16 proline was implicated in this activity.
Other investigators have also examined C-peptide frag-
ment bioactivity using Na+,K+-ATPase activity in rat re-
nal tubular segments as a readout [10]. Two segments of
C-peptide demonstrated functional importance. The rat
C-peptide carboxy terminal pentapeptide, EVARQ, elicited
100% of the activity of intact C-peptide whereas the remain-
ing portion of the molecule, lacking this 5 amino acid se-
quence, was totally inactive. In this rat system, the terminal
pentapeptide of human C-peptide (EGSLQ) elicited 75% ac-
tivity; and notably the glutamic acid at position 1 and the2 Experimental Diabetes Research
glutamine at position 5 are generally conserved in mam-
mals. Similar well-deﬁned C-terminal functional sequences
are also found in gastrin and cholecystokinin. Overall, the
behaviour of the C-termimal pentapeptide in these studies
was typical of a peptide ligand interacting with a speciﬁc re-
ceptor. In contrast, several C-peptide midregion sequences
were able to partially recapitulate the activity of the intact
molecule but exhibited rather diﬀerent properties. Activity
relating to this region was not seen with the des-(27–31)-C-
peptide,andseveralnonnaturalD-aminoacidcontainingse-
quences showed some activity. The activity of these segments
decreased if they were greater than 9 amino acids in length.
This behaviour is not reminiscent of peptide-receptor inter-
actions, but similar to the nonspeciﬁc type interactions of
C-peptide with plasma membranes postulated by Ido et al.
[9].
How the balance of activity provided by these two re-
gions of the C-peptide molecule is manifest in vivo is not
well understood. Very recent work suggests that eﬃcient ac-
tivation of signalling pathways requires the presence of con-
served glutamic acid residues at positions 3, 11, and 27 of C-
peptide, and the presence of helix-promoting residues in the
N-terminal segment [11]. Taken together with the data relat-
ing to its carboxy-terminus, the overall picture now emerg-
ing of the structure-activity relationship of the C-peptide
molecule is one of a tripartite structure where the termi-
nal sections are involved in functional interactions, with the
midregion forming a joining segment [11].
Analysis of rhodamine-labelled human C-peptide bind-
ing to a variety of human-cell membranes has now been car-
ried out using highly sensitive ﬂuorescence correlation mi-
croscopy, allowing measurement of membrane interactions
at the single-molecule level in sub-fL volumes [12]. High-
aﬃnity speciﬁc binding of C-peptide was observed with an
association rate constant of ∼3nM; half-maximal occupa-
tion of binding sites was seen at 0.3nM C-peptide; and full
occupation at 0.9nM C-peptide. The maximal number of
binding sites, approximately 1000–1500 per cell, was found
on human renal tubular cell membranes. Binding could be
displaced by excess intact C-peptide and by the C-terminal
pentapeptide, but not by a randomly assembled scrambled
C-peptide, insulin, and insulin-like growth factor (IGF)-I
or IGF-II. Importantly, binding of C-peptide could also be
largely inhibited by pertussis toxin (PTX) pretreatment of
cells[12].Overall,theseresultsstronglysupporttheexistence
of a speciﬁc GTP-binding protein-coupled receptor (GPCR)
for C-peptide, linked either to the G-protein α-subunit Gαi
or Gαo, which interacts with the C-terminal penatpeptide re-
gion of the C-peptide molecule.
Attempts to identify a C-peptide receptor by gene-clon-
ing strategies or using proteomic approaches have, to date,
been unsuccessful. Luzi et al. recently reported their inability
to isolate a C-peptide receptor either by screening a human
lung ﬁbroblast λphage cDNA expression library or by pro-
teomic analysis of proteins co-immunoprecipitated from C-
peptide treated human ﬁbroblasts using anti-C-peptide anti-
bodies[13].Thisinformationwaspublishedinthecontextof
a short-debate paper and therefore methodological descrip-
tion was by necessity brief. Certainly this data does not prove
that a receptor does not exist, and it remains perfectly possi-
ble however that alternative methodologies may successfully
identify a C-peptide receptor in the future. Eﬀort in this area
is well justiﬁed and urgently needed.
3. C-PEPTIDE AND THE NA+,K+-ATPASE
Na+,K+-ATPase is an ubiquitous membrane-associated pro-
tein complex that uses energy from the hydrolysis of ATP to
drive the counter-transport of sodium and potassium across
the plasma membrane. It is widely accepted that impaired
Na+,K+-ATPase activity is present in a variety of cell types
in diabetes and contributes to the pathogenesis of diabetic
complications [14–17]. The ﬁrst indications that C-peptide
may regulate the activity of intracellular enzymes came from
studies of the Na+,K+-ATPase.
ThekidneytubuleisaparticularlyrichsourceofNa+,K+-
ATPase and Ohtomo et al. described activation of this en-
zyme by rat C-peptide in rat kidney tubules at low to
high nanomolar concentrations [18]. This eﬀect was abol-
ished by PTX and, being inhibited by the Ca2+-calmodulin-
dependent protein phosphatase 2B (calcineurin) inhibitor
FK506, appeared dependent on intracellular Ca2+ concen-
tration. Interestingly the stimulatory eﬀect of C-peptide on
Na+,K+-ATPase in these experiments was substantially aug-
mented by neuropeptide Y (NPY).
Extending these ﬁndings, the same group of investi-
gators studied the ability of C-peptide fragments to acti-
vate Na+,K+-ATPase in rat kidney proximal tubule segments
[10]. Altogether 36 diﬀerent peptides and amino acids corre-
sponding to various regions of intact C-peptide were inves-
tigated. Carboxy-terminal tetra- and penta-peptides elicited
full activity whilst midregion peptides elicited only par-
tial activity at best. These results were in broad agreement
with those of Ido et al. [9] (discussed above) and those of
the C-peptide binding studies published the following year
[12], and, overall, they supported the nascent concept of C-
peptide binding to a speciﬁc receptor with subsequent acti-
vation of downstream eﬀector enzymes.
Motivated by these observations of C-peptide-induced
increases in Na+,K+-ATPase activity and associated improve-
ments in nervous system and renal function, it was hypoth-
esised that the low C-peptide levels and reduced Na+,K+-
ATPase activity in erythrocyte membranes observed in type
1 diabetes may be related. Accordingly, it was found that in
patients with type 1 diabetes and complete C-peptide deﬁ-
ciency, erythrocyte activity Na+,K+-ATPase was consistently
lower than healthy controls [19]. In type 2 diabetes, ery-
throcyte Na+,K+-ATPase was signiﬁcantly lower in insulin-
treated patients than in those treated with oral hypogly-
caemic agents. Indeed the fasting C-peptide level was the
only variable studied that independently correlated with
Na+,K+-ATPase activity [19]. Subsequently, it was shown
that infusion of C-peptide into patients with type 1 dia-
betes resulted in an increase in plasma cGMP and erythro-
cyte membrane Na+,K+-ATPase activity. A C-peptide dose
response was evident in these studies where maximal ef-
fects were observed with achieved plasma C-peptide lev-
els of ∼3.5nM [20]. Similar improvements in rat nerveC. E. Hills and N. J. Brunskill 3
Na+,K+-ATPase activity and function have also been ob-
served after exogenous administration of C-peptide [9].
Themechanism(s)bywhichC-peptideactivatesNa+,K+-
ATPase has been examined. Using isolated rat kidney medul-
lary thick ascending limb tubules (MTALs) C-peptide was
found to activate Na+,K+-ATPase at physiological concentra-
tions [21]. In addition, treatment of MTALs with C-peptide
resultedinphosphorylationoftheNa+,K+-ATPaseα-subunit
and translocation of the Ca2+-dependent protein kinase C
(PKC)-α to the membrane, an index of its activation. Both
of these latter eﬀects were blocked by an inhibitor of PKC
[21].
Overall, the studies of Na+,K+-ATPase activity have de-
lineated a stimulatory signalling action of C-peptide at phys-
iologicalconcentrationsdependentonintracellularCa2+ and
PKC,andsensitivetoPTXsuggestingthepresenceofaGPCR
for C-peptide. Replacement of C-peptide in diabetic animals
and patients with diabetes has a salutary eﬀect on Na+,K+-
ATPase activity in a variety of tissues aﬀected by diabetic
complications.
Prompted by this evidence linking C-peptide to the
Na+,K+-ATPase, and mindful that vasopressin also stimu-
lates Na+,K+-ATPase activity, Maestroni et al. [22] studied
C-peptide eﬀects on a recently described vasopressin recep-
tor; the vasopressin-activated calcium mobilising receptor
(VCAM-1). They found that in human skin ﬁbroblasts and
human mesangial cells, C-peptide increased expression of
VCAM-1 at both RNA and protein levels [22]. The eﬀect
wasmaximalwith1nM C-peptide and inhibited by PTX.Al-
though no direct link between C-peptide-induced increases
in VCAM-1 and enhanced Na+,K+-ATPase activity was stud-
ied, enhancement of vasopressin action via upregulation of
VCAM-1 provides a further mechanism for C-peptide action
relating to the Na+,K+-ATPase.
4. THE EFFECT OF C-PEPTIDE ON ENDOTHELIAL
NITRIC OXIDE SYNTHASE (eNOS)
One consistent observation following in vivo administration
of C-peptide in type 1 diabetes is augmentation of microvas-
cularbloodﬂowtotissuesandorgansincludingmuscle,skin,
and kidney [23]. The possibility that these eﬀects could be
mediated by C-peptide regulation of nitric oxide (NO) was
ﬁrst provided by the ﬁnding that increased glucose utilisa-
tion in streptozotocin diabetic rats stimulated by C-peptide
was sensitive to inhibition of NOS by coadministration of N-
monomethyl-l-arginine (L-NMMA) [24]. This ﬁnding was
in agreement with earlier studies that described an NO-
dependent pathway for glucose transport and metabolism
by muscle tissue [25, 26]. Subsequently, it was demonstrated
thatthatC-peptidemediatedarteriolardilatationwasdepen-
dent on NO [27, 28].
Details of the mechanism underlying C-peptide’s ability
to increase NO production have been provided by Wallerath
et al. [29]. Working with a bovine aortic endothelial cell
model (BAEC), these investigators reported that at the phys-
iological postprandial concentration of 6.6nM, C-peptide
stimulated NO release consequential upon a rise in intra-
cellular Ca2+. These authors speculated that C-peptide sig-
nalling resulted in activation of the Ca2+-sensitive endothe-
lial NOS (eNOS) following increased Ca2+ inﬂux, thus ex-
plaining in large part the vasodilatory eﬀects of C-peptide
observed in vivo [29].
Other workers have demonstrated upregulation of eNOS
expression by C-peptide. In BAEC, enhanced NO release
stimulated by C-peptide was accompanied by upregulation
of eNOS gene transcription [30]. This eﬀect appeared to be
dependent on the upstream phosphorylation and activation
of extracellular signal-regulated mitogen activated protein
kinase (ERK).
Activation of the NO system by C-peptide signalling may
also have other consequences. In C-peptide, injected rats ex-
pression of eNOS is increased as is basal aortic NO pro-
duction. Reduced cell surface expression of the adhesion
molecules P-selectin and ICAM-1 on the microvascular en-
dotheliumwasobservedandasaresultleukocyte/endothelial
interactions were attenuated [31].
5. STIMULATION OF MITOGEN ACTIVATED PROTEIN
KINASES (MAPKs) BY C-PEPTIDE
The MAPKs are evolutionary conserved enzymes that link
cell-surface receptors or chemical and physical stresses to key
regulatory targets within cells [32–34]. MAPKs phosphory-
late multiple targets on serine and threonine and, as a result,
control many critical cell functions such as growth, gene ex-
pression, and cell survival and adaptation. The MAPK family
includes the ERKs 1 and 2, c-Jun N-terminal kinases (JNK1,
JNK2, JNK3), p38s (p38α,p 3 8 β,p 3 8 γ,p 3 8 δ), and ERK5.
In recent years, several reports have described the abil-
ity of C-peptide to induce phosphorylation and activation of
members of the MAPK family. The initial impetus for study
in this area is developed from the earlier observations of syn-
ergy between C-peptide and NPY signalling in the activa-
tion of Na+,K+-ATPase [18]. NPY is well known to activate
MAPK [35, 36] and this ﬁnding therefore prompted Kita-
mura and colleagues to study possibility of MAPK mediated
C-peptide signalling in the mouse embryonic ﬁbroblast cell
line, Swiss 3T3 [37]. Using both immunoblotting of phos-
phorylated ERK1 and ERK2 with phosphospeciﬁc antisera
and an in vitro kinase assay as readouts of ERK activation,
these workers showed that incubation of 3T3 cells with C-
peptide resulted in brisk activation of ERK evident at a con-
centration as low as 1pM and maximal with 1nM C-peptide
[37]. This stimulatory eﬀect was also seen with NPY, and ac-
tivation of ERK by both NPY and C-peptide was abolished
by PTX. Neither retrosequenced nor all D-amino acid hu-
man C-peptide stimulated ERK. Not all cell types tested by
these workers responded to C-peptide with ERK activation.
No eﬀect was seen in 3T3-L1 cells, L6E9 muscle cells, HepG2
hepatomacells,NG108.15neuroblastomacells,orC6glioma
cells [37].
Activation of ERK is involved in eNOS gene transcrip-
tion, an event previously also shown to be increased by C-
peptide (see above). In an attempt to link these phenom-
ena, studies were performed in LEII mouse lung capillary4 Experimental Diabetes Research
endothelial cells to examine the ability of C-peptide to ac-
tivate transcription factors [38] .I nt h i sc e l lt y p e ,C - p e p t i d e
stimulatedbothp38andERKMAPKactivities,butnotc-Jun
N-terminal kinase. By comparison, insulin was only able to
activate ERK but not p38 MAPK. In addition, C-peptide ac-
tivated the cAMP response element (CRE)-binding protein
(CREB)/activating transcription factor-1 (ATF-1) in a p38
but not ERK-dependent manner, thereby causing binding of
these transcription factors to CRE. Consequently, it was con-
ﬁrmed that enhanced eNOS transcription in BAECs follow-
ing C-peptide treatment was indeed MAPK-dependent [39].
Therefore diﬀerences in C-peptide responses between vari-
ous cell types clearly exist. In BAECs, ERK activation is re-
quired for eNOS transcription, whereas transcription factor
activation in LEII cells follows C-peptide stimulation of p38.
Loss of renal tubular cells is a prominent feature of di-
abetic nephropathy. It is therefore of signiﬁcance that tubu-
lar cell growth and survival may be modulated by C-peptide
signalling. In the opossum kidney (OK) immortalised prox-
imal tubular cell line C-peptide also potently activates ERK,
maximally at a concentration of 300pM and declining there-
after with a bell-shaped dose-response curve [40]. Further-
more, C-peptide also induced activation of Akt in OK cells.
This event was sensitive to wortmannin and indicative of
phosphatidylinositide-3-kinase(PI-3-kinase)activation.The
dose-response curve for Akt activation revealed a maxi-
mal eﬀect at a C-peptide concentration of 5nM, remain-
ing constant thereafter up to a C-peptide concentration of
100 nM, and thus being quite distinct from that for ERK
activation. In addition, C-peptide caused an inﬂux of Ca2+
into the OK cells upon which a consequent translocation
and activation of PKCα were absolutely dependent [40].
These ﬁndings are in agreement with the earlier studies of
Tsimaratos et al. that showed PKC-induced activation of
kidney Na+,K+-ATPase in C-peptide exposed tubular seg-
ments [21] (see above). Most importantly, these signalling
events had a functional consequence with signiﬁcant en-
hancement of proliferation seen in C-peptide treated cells
[40]. All of these events were sensitive to PTX again pro-
viding evidence of the likely presence of a GPCR for C-
peptide.
Most recently C-peptide has been found to promote
translocation of the low molecular weight GTP-binding pro-
tein, Rho A, from the cytoplasm to the membrane of human
kidneyproximaltubularcells[41].Thiseﬀectwascompletely
reliantontheupstreamactivationofphospholipaseC(PLC).
In fact, in these cells the activation of ERK, JNK, as well as
PKC-ε and -δ was each sensitive to PLC inhibition, indicat-
ing an obligate dependency on upstream PLC activation by
C-peptide. Once more, all stimulatory eﬀects of C-peptide
were PTX sensitive [41].
The molecular mechanisms by which C-peptide activates
MAPK can now be described with some precision. The sig-
nal transduction pathway involves: (i) C-peptide binding to
a PTX sensitive GPCR; (ii) the activation of PLC; (iii) subse-
quently increased diacylglycerol and intracellular Ca2+ levels
stimulate several PKC isoforms; (iv) PKC-dependent activa-
tion and translocation of RhoA to plasma membrane; and
(v) phosphorylation and activation of MAPKs.
6. C-PEPTIDE ACTIVATION OF PI-3-KINASE
The PI 3-kinases are a family of enzymes that phosphorylate
the hydroxyl group at the 3 positions of the inositol ring of
phosphatidyinositol. PI-3-kinases regulate a remarkably di-
verserangeof cellularfunctions,including growth,prolifera-
tion, survival, diﬀerentiation, motility, and intracellular traf-
ﬁcking [42]. The PI-3-kinases are also a key component of
insulin signalling pathways and this is of substantial interest
in diabetes. Many of these functions of PI-3-kinase are re-
lated to their ablilty to activate protien kinase B (Akt) [42].
RobustC-peptide activation of PI-3-kinase hasnow been
demonstrated by several authors in various cell types. As a
result, it is known that physiological concentrations of C-
peptide can regulate several aspects of PI-3-kinase signalling
pathways in OK cells [40], Swiss 3T3 ﬁbroblasts [37], SH-
SY5Y neuroblastoma cells [43], human CD4+T cells [44]L 6
myoblasts [45]. As a direct consequence, it is now recognised
that stimulation of PI-3-kinase by C-peptide acting alone
is responsible for (i) enhancement of neuronal and kidney
tubular cell proliferation [40, 43]; (ii) increased T cell mi-
gration [44]; (iii) stimulation of peroxisome proliferators-
activatedreceptor-γ (PPARγ)inkidneytubulecellsandasso-
ciated gene transcription [46]; and (iv) upregulated glycogen
synthesis in skeletal muscle cells [45].
7. EFFECTS OF C-PEPTIDE
ON TRANSCRIPTION FACTORS
Given that many of the changes in cell phenotype that take
p l a c ea sar e s u l to fs i g n a l l i n gb yb i o a c t i v em o l e c u l e sa r em e -
diated by altered gene and protein expression, it is not sur-
prising that C-peptide regulates activity of several key tran-
scription factors.
Extending their observations of C-peptide activation of
MAPKs Kitamura et al. described phosphorylation and ac-
tivation of CREB, ATF-1, and ATF-2 in LEII cells [38]. In-
deed 1nM C-peptide and phorbol ester, a positive control,
were equipotent in this regard. CREB and ATF proteins are
transcription factors that bind when activated to speciﬁc re-
sponse elements, CRE, in DNA thereby regulating transcrip-
tion. Gel mobility shift assays clearly showed the binding
of CREB to CRE in C-peptide treated cells. In the latter
study, speciﬁc genes subject to regulation were not identi-
ﬁed. However using neuroblastoma cells, it was reported that
C-peptide treatment enhanced expression and translocation
of nuclear factor-κB( N F - κB) and expression of the Bcl2
protein—an important mediator of the antiapoptotic eﬀects
governed by NF-κB[ 43]. Control of NF-κBb yC - p e p t i d e
in Swiss 3T3 has also been demonstrated. In these cells,
1nM C-peptide activated transcription of cyclooxygenase-
2( C O X - 2 )v i aN F - κB consequent upon upstream activation
of PKC [47]. COX-2, a cytokine inducible gene, is the rate-
limiting enzyme in the conversion of arachidonic acid to
prostaglandin, but the potential consequences of its upreg-
ulation by C-peptide remain unclear.
We performed detailed studies of transcription factor
activation in OK proximal tubular cells [46, 48], compar-
ing C-peptide eﬀects to those of insulin and focussing onC. E. Hills and N. J. Brunskill 5
PPARγ and NF-κB. A member of the nuclear hormone re-
ceptor family, PPARγ is the target for the insulin-sensitising
thiazolidinediones currently used as therapeutic agents in
the treatment of type 2 diabetes [49]. The expression of
PPARγ may also be regulated by insulin [50]. Using transient
transfection of a peroxisome proliferator response element
(PPRE)-luciferase reporter construct, we showed that both
C-peptide and insulin transactivated PPRE via PPARγ [46].
C-peptide (EC50 4nM) was more potent than insulin (EC50
10nM) in this regard, but both agents evoked phosphory-
lation of PPARγ similarly via activation of PI-3-kinase. One
consequence of PPARγ activation by C-peptide and insulin
was enhanced transcription of the prototypic PPARγ regu-
lated gene, CD36 [46]. Clearly, therefore, there is a degree of
overlap between insulin and C-peptide signalling with both
agent’s eﬀects being directed via PI-3-kinase towards PPARγ.
However, only the eﬀects of C-peptide were attenuated by
PTX and therefore C-peptide must be signalling through a
receptor system fundamentally distinct from that of insulin.
These data indicate an important novel mechanism whereby
C-peptideandinsulinmayinteracttoregulateglycaemiaand
the expression of PPAR regulated genes such as those in-
volved in metabolic control and inﬂammation.
The next step was to establish proof of principle that
C-peptide had the capacity to act as a protective agent in
diabetic nephropathy. To this end, we investigated whether
C-peptide could counteract adverse eﬀects precipitated by
the administration of TNF-α to OK proximal tubular cells
[48]. TNF-α is recognised as a major player in the develop-
ment of diabetic nephropathy and may contribute to tubular
cell apoptosis and tubular atrophy prominently observed in
diabetic nephropathy [51–55]. TNF-α is a pleiotropic pep-
tide cytokine, capable of eliciting a wide spectrum of cellu-
lar responses including diﬀerentiation, proliferation, inﬂam-
mation, and cell death via interaction with two members of
the TNF receptor family, TNF-R1 and TNF-R2 [54]. Pre-
dominantly produced by monocytes/macrophages but also
by T and B-lymphocytes and glomerular mesangial cells
[55, 56], TNF-α binding to TNF-R1 may simultaneously
trigger apoptotic pathways by recruitment of death eﬀec-
tor adaptor molecules with subsequent activation of caspase
cascades, and antiapoptotic pathways by a pathway involv-
ing TNF receptor-associated factor2 (TRAF2) and nuclear
factor-κB( N F - κB). Integration of these events determines
the eventual cellular response to TNF-α stimulation. In par-
ticular NF-κB stimulates transcription of antiapoptotic fac-
tors that modulate the caspase cascade, and thus NF-κBa c -
tivity acts as a checkpoint in a cell’s decision to survive or
apoptose in response to a given stimulus.
When applied to OK cells, TNF-α markedly reduced vi-
ability and induced apoptosis [48]. This was completely pre-
vented by pretreatment with insulin or C-peptide. At the
same time both insulin and C-peptide activated NF-κBa s
judged by luciferase reporter assay. Insulin demonstrated a
typical sigmoidal dose-response of NF-κB activation, max-
imal at an applied concentration of 100nM. On the other
hand, C-peptide displayed completely diﬀerent bell-shaped
curve of NF-κB stimulation, maximal with a 5nM applied
concentration. As in previous studies, PTX blocked only the
C-peptide eﬀect. However in these studies, the presence of a
Gαi-linkedGPCRwasrevealedusinganadditionaltechnique
whereby C-peptide but not insulin was shown to stimulate
GTPγS binding to Gαi in OK cell membranes. In this work,
the ability of C-peptide to prevent TNF-α-induced apoptosis
appeared to be due to its ability to induce the expression, via
NF-κB activation, of survival genes such as TRAF2 [48].
This study provided evidence for the ability of C-peptide
to regulate the expression of beneﬁcial genes in the face
of pathophysiological stimuli relevant to the development
andpathologyofdiabeticnephropathy.Again,C-peptideap-
peared to be acting via Gαi, and although C-peptide shared
somesignallingpropertieswithinsulinitclearlypossessedits
own unique signalling capabilities.
8. IS C-PEPTIDE AN INSULIN MIMETIC?
T h e r ei sn od o u b tt h a ts o m ec o m p o n e n t so fC - p e p t i d es i g -
nalling pathways are shared with those of insulin. For ex-
ample, activations of MAPKs and PI-3-kinase are well de-
scribed downstream events following insulin-insulin recep-
tor interactions [57]. In the absence of a fully characterised
C-peptide receptor, and given that C-peptide exhibited some
insulin-like actions such as increasing muscle glucose trans-
port[58,59],Grunberger etal. wondered whetherC-peptide
signalling may simply be explained by activation of the in-
sulin receptor signalling system. They found in L6 myoblasts
that C-peptide (0.3–3nM) activated insulin receptor tyro-
sine kinase, tyrosine phosphorylation of the insulin recep-
tor substrate-1 (IRS-1), MAPK, PI-3-kinase, p90 ribosomal
S6 kinase (p90RSK) and glycogen synthase kinase-3 (GSK3),
and glycogen synthesis [45]. Submaximal concentrations of
insulin and C-peptide were additive in eﬀect, whereas maxi-
malconcentrationswerenot.C-peptidestimulationofglyco-
gen synthesis was not abrogated by PTX, although earlier
speciﬁc steps in the signalling pathway were not tested in
thisway[45].TheseﬁndingscontrastedwiththoseofZierath
etal.whofoundnoevidenceofinsulinreceptoractivationby
C-peptide in human skeletal muscle [59]. Nonetheless their
results led Grunberger et al. to speculate that, amongst other
possibilities, C-peptide per se may activate the insulin recep-
tor [45].
There are several lines of evidence against this however.
The most compelling is the description by multiple authors
of the speciﬁc PTX sensitivity of C-peptide eﬀects, and most
recently the observation that C-peptide provokes GTPγS
bindingtoGαi,[48]anobservationcompatiblewithguanine
nucleotide exchange occurring on a G-protein after ligation
of a GPCR. Furthermore, the dose-response curves for in-
sulin are typically sigmoidal whereas those for C-peptide are
often bell shaped with a diminution of activity at higher con-
centrations. At least in vitro C-peptide appears more potent
on a molar basis than insulin. Typically C-peptide signalling
eﬀects are apparent at midhigh pM concentrations, maximal
at ∼1–5nM and thereafter decline. In contrast, insulin re-
sponses generally become evident at ∼10nM increasing up
to 100–1000nM where they plateau. Finally, using plasmon
resonance no interaction of C-peptide with soluble puriﬁed6 Experimental Diabetes Research
Table 1: Signalling elements activated by C-peptide according to cell type studied (for abbreviations see text).
Cell type studied
Signalling element Kidney tubular Muscle Fibroblasts Endothelial Erythrocytes Neuroblastoma CD4 + T Cells Nerve
Na+,K+-ATPase + + +
↑[Ca2+]i ++
PKC + +
NO release + +
ERK + + + +
p38 MAPK +
JNK +
PLC +
p90RSK +
GSK3 +
PI3K + + + + +
CREB +
NF-κB+ + +
PPARγ +
insulin receptor A or insulin-like growth factor receptor was
detected in a very recent study [60].
The balance of evidence suggests that C-peptide medi-
ates its own distinct signalling through a GPCR. There is
certainly some overlap between the signalling pathways ac-
tivated by C-peptide and insulin but this is a common obser-
vation in biological systems. Crosstalk between GPCR acti-
vated signalling and receptor tyrosine kinase activated path-
ways occurs by transactivation. This well-described mech-
anism of cross-communication between signalling systems
enables the cell to integrate multiple signals derived from its
environment.Transactivationoftheepidermalgrowthfactor
receptorfollowingagoniststimulationofGαi orGαq coupled
GPCRs represents the paradigm for this system, however
similar events have now been described for the platelet de-
rived growth factor receptor, the insulin-like growth factor-1
receptor, and IRS-1.
9. SUMMARY AND CONCLUSION
In the last 10 years, there has been a revolution in think-
ing about C-peptide. There can now be no doubt that C-
peptide truly exerts a variety of biological eﬀects. These ef-
fects are underpinned by solid evidence of cell signalling
events (summarised in Table 1), most likely mediated via a
speciﬁc GPCR. The concentrations of C-peptide required to
elicit signalling outputs are entirely congruent with what is
known about binding aﬃnities of C-peptide for its putative
receptor. It should be acknowledged however that the lack of
detailed identiﬁcation/cloning of a receptor remains a weak-
ness in the ﬁeld. Nonetheless, the importance of these sig-
nallingeﬀectscannotbeunderestimated.Thepathwaysstim-
ulated are fundamental to cell function and phenotype, im-
pacting on such basic processes as life and death. The next
challenge is to identify the receptor and to bring C-peptide
nearer to the clinical arena in order to test its potential ben-
eﬁts in ameliorating the devastating consequences and com-
plications of diabetes.
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